Background: Compared to the general population, those who suffer from severe mental illness, particularly schizophrenia, have greater rates of morbidity and mortality. The present study was conducted to assess drug-emergent metabolic syndrome in psychiatric patients. Materials & Methods: 120 patients suffering of schizophrenia of both genders were divided into three subgroups, i.e. subgroup I, subgroup II, and subgroup II, who were prescribed risperidone, olanzapine, and clozapine respectively. Group IV was a control group who were prescribed haloperidol. After one month and four months, respectively, measurements were made of the waist circumference, fasting HDL levels, fasting triglycerides, fasting blood pressure, and fasting blood glucose. Results: Out of 120 patients, 78 were males and 44 were females. Metabolic syndrome was seen in 12 in group I, 10 in group II, and 8 in group III. The difference was significant (P< 0.05). The mean fasting HDL was 52.4, 46.2, 45.6, and 46.5 in group I, II, III and IV respectively. The mean WC was 75.6, 76.2, 77.4, and 76.0 in group I, II, III and IV respectively. The mean HC was 84.5, 82.2, 83.1, and 82.2 in group I, II, III and IV respectively. The mean FBG (mg/dl) in group I, II, III and IV was 79.2, 80.5, 77.2 and 76.4 respectively. The mean fasting TG was 80.3, 88.4, 81.2, and 75.4 in group I, II, III and IV respectively. The difference was significant (P< 0.05). Conclusion: Second-generation antipsychotics significantly change metabolic parameters, increasing the risk of metabolic syndrome and associated diseases such type II diabetes and cerebrovascular accidents. Olanzapine is the antipsychotic drug that has the greatest potential to cause metabolic syndrome.